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Background
We analyzed and integrated transcriptome data from two large studies of lung adenocarcinomas on distinct populations. Our goal was to investigate the variable gene expression
alterations between paired tumor-normal tissues and prospectively identify those alterations
that can reliably predict lung disease related outcomes across populations.

Methods
We developed a mixed model that combined the paired tumor-normal RNA-seq from two
populations. Alterations in gene expression common to both populations were detected and
validated in two independent DNA microarray datasets. A 10-gene prognosis signature was
developed through a l1 penalized regression approach and its prognostic value was evaluated in a third independent microarray cohort.

Results
Deregulation of apoptosis pathways and increased expression of cell cycle pathways were
identified in tumors of both Caucasian and Asian lung adenocarcinoma patients. We demonstrate that a 10-gene biomarker panel can predict prognosis of lung adenocarcinoma in both
Caucasians and Asians. Compared to low risk groups, high risk groups showed significantly
shorter overall survival time (Caucasian patients data: HR = 3.63, p-value = 0.007; Asian
patients data: HR = 3.25, p-value = 0.001).

Conclusions
This study uses a statistical framework to detect DEGs between paired tumor and normal tissues that considers variances among patients and ethnicities, which will aid in understanding
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the common genes and signalling pathways with the largest effect sizes in ethnically diverse
cohorts. We propose multifunctional markers for distinguishing tumor from normal tissue and
prognosis for both populations studied.

Introduction
Among different ethnic populations, cancers often present with distinct clinical characteristics
in incidence, prevalence, mortality and drug response [1]. The heterogeneity among ethnic
groups can be caused by extrinsic environmental factors or intrinsic genetic factors that are
population specific. Extrinsic factors such as environment, smoking, or dietary habits, have
been shown to contribute to a large proportion of variation in cancer susceptibility [2, 3]. In the
past decades, the possible role of intrinsic factors such as genetic variation in cancer heterogeneity is gradually attracting researchers’ attention. For example, smoking-related risk of lung
cancer is found to be significantly different among populations, which might be due to the
between-ethnic variation in the metabolism of nicotine [4]. Similar discrepancies have been
observed with biomarkers. Many molecular biomarkers such as mRNAs, proteins, autoantibodies, microRNAs, and cell-free DNA have been identified as candidate biomarkers for diagnosis
and treatment in cancer, but few of them have been validated. Variations in genetic architecture
among different ethnic groups make it difficult to validate cancer risk associated SNP markers
[5]. In the current study, we hypothesized that integrating data across different populations will
identify robust biomarkers by taking between-ethnic genetic variation into account. Here, we
focused on the most prevalent lung cancer type, adenocarcinoma. Previous studies have identified lung cancer risk variants including mutations in EGFR [6], HER2 [7], BRAF [8] or KRAS
[9], and gene fusions of RET, ALK or ROS1 [10]. However, information on gene expression in a
tumor adds biological context to lung cancer prognosis by identifying differentially expressed
genes and inferring pathway activation. We analysed datasets from two cohort studies for Caucasians and Asians, which were generated by RNA sequencing (RNA-seq) [11].
In studies of cancer, comparing paired tumor and anatomically matched-adjacent normal
tissues is an effective approach to alleviate the bias from patient variations as well as systematic
error. In our study, we analyzed RNA-seq data from 58 primary solid tumors and anatomicsite matched normal tissue pairs from The Cancer Genome Atlas (TCGA) with patients selfidentified as Caucasian [12]. Another dataset analyzed 77 primary solid tumor and anatomicsite matched normal tissue pairs from lung adenocarcinoma patients with Korean and East
Asian descent [13]. By investigating gene expression patterns in these two populations, we
found heterogeneous expression changes in Caucasians and Asians. Considering both population-specific and patient-specific genetic architectures, a mixed model was proposed to identify the candidate biomarkers adjusting tissue, ethnicity, as well as other latent confounding
factors in the two cohorts. As a result, a set of consistent differentially expressed genes (DEGs)
in Caucasians and Asians was identified. Using those cohort-common DEGs as possible candidates for predicting survival outcomes, we also selected a panel of transcriptome markers for
lung adenocarcinoma prognosis for both Caucasian and Asian patients.

Methods
Datasets and pre-processing procedures
Two RNA-seq and three DNA microarray datasets were used in this study (Table 1), including
the following:
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Table 1. Datasets used.
Accession

Platform

Name

Population

Paired

Survival data
available

RNA-seq

Caucasian-seq

Caucasian

Yes

Yes

Asian-seq

Asian

Yes

GSE40419[13]

Caucasian-array

Caucasian

Yes

GSE19804[14]

Asian-array

Asian

Yes

GSE8894

Asian

Microarray

TCGA[12]

GSE10072[15]
Yes

GSE8894[16]

https://doi.org/10.1371/journal.pone.0175850.t001

Caucasian RNA-seq study. We downloaded an Illumina HiSeq 3.1.12.0 lung adenocarcinoma RNA-seq dataset from the TCGA database [12]. The dataset contains 457 tumor and 58
paired normal tissues, in which 53 pairs were from Caucasian patients. 2x48 bp pair-end
RNA-seq reads were aligned to the Ensembl GRCh37 human reference genome by MapSplice
[17]. Read counts of each gene were then estimated by RSEM [18]. The overall survival data
and clinical variables of the patients were also downloaded from TCGA.
Asian RNA-seq study. Tumor and normal paired RNA-seq data of 77 lung adenocarcinoma patients were downloaded from Gene Expression Omnibus (GEO) with the accession
number GSE40419 [13]. 100-bp pair-end reads were generated from Hiseq sequencing platform. We used Tophat to align reads to the Ensembl GRCh37 human reference genome and
HTSeq to calculate the counts mapped to each gene [19, 20]. Clinical information of the
patients was downloaded from the public website (http://genome.cshlp.org/content/22/11/
2109/suppl/DC1).
Three microarray studies. We also used three microarray datasets for validation, which
were available in NCBI GEO database under accession numbers GSE19804, GSE10072 and
GSE8894. All three mRNA expression DNA microarray-derived datasets were generated with
Affymetrix GeneChip Human Genome U133 Arrays. Both GSE19804 and GSE10072 studied
tumor and paired normal tissues. 60 Asian patients in Taiwan were enrolled in the GSE19804
study [14] and gene expression data from 33 Caucasian patients were available in the
GSE10072 study [15]. Gene expression raw signals from GSE19804 and GSE10072 studies
were processed and normalized using the robust multiarray average (RMA) expression measure method [21]. We used the GSE8894 dataset to validate selected prognosis markers, in
which transcriptome expression and recurrence-free survival information of 62 Asian patients
were available [16]. We downloaded GCRMA normalized data of all probe sets from the
GSE8894 study. For genes with multiple probes, the probe with the maximum average expression values in all samples was selected to represent the gene expression.

Mixed effect models
Reads per kilobase per million mapped reads (RPKM) values were calculated from RNA-seq
gene counts, and were log2 transformed to improve normality. Then we imputed missing values using the K-nearest neighbor method [22].
Because of the dependency of measurements within a patient from a specific population,
for each gene, we applied a mixed effect linear model,
logitðPrðyi ¼ 1ÞÞ ¼ xiT b þ ziT g þ qTi d þ ε

ð1Þ

to detect tumor-normal DEGs. Here, yi is the dichotomous outcome for the i-th patient
which is 1 for tumor tissue and 0 for normal tissue. For the i-th patient, xi indicates a vector
of variables representing the log2 scaled RPKM values for a set of p genes (xi1,xi2,xi3,. . .,xip)T.
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β = (β1,β2,β3,. . .,βp)T is a vector of regression coefficients to be estimated. When detecting
DEGs, we performed a gene-wise testing in which p = 1. zi and qi are indexes of patient ID and
populations (Caucasians and Asians), respectively, which account for subject-specific effects. γ
and δ are unknown vectors of random effect regression coefficients that model the effects from
populations and individuals, respectively, whereas E(γ) = 0 and E(δ) = 0. The restricted maximum likelihood (REML) method was used to estimate parameters β, γ and δ. F-test was performed to test the association of gene expression with the disease outcome in the full model
(Eq 1) comparing to the following null model without gene expression variables (Eq 2) as
logitðPrðyi ¼ 1ÞÞ ¼ ziT g þ qTi d þ ε

ð2Þ

p-values were adjusted to control the multiple testing false discovery rate using the BenjaminiHochberg method.
We also tested the DEGs in each specific population with the full and null models shown in
Eqs 3 and 4, in which the population effect qi was null within one specific population,
logitðPrðyi ¼ 1ÞÞ ¼ xiT b þ ziT g þ ε

ð3Þ

logitðPrðyi ¼ 1ÞÞ ¼ ziT g þ ε

ð4Þ

Biomarker selection
Logistic regression and Cox proportional hazard model were used for tumor-normal classification and prognosis prediction separately. The l1 penalized regression technique LASSO was
used to select predictive genes as potential biomarkers [23]. For the i- th patient, we still use
the vector xi to denote the expression of a set of biomarker candidates, and hi to denote the log
odds of cancer outcome or log hazard ratio of death. The regression coefficients βs were estimated with the l1 penalized term λ||β||2 according to Eq 5 as
^ ¼ argmax ½k xT b
b
b
i

hi k2

l kbk2 

ð5Þ

where λ was a tuning factor which was determined by minimizing the deviance.
^ larger than 0 were considered as potential predictive biomarkers. To evaluVariables with b
ate the goodness of model fitting, we used the 5 fold cross validation strategy by randomly
splitting data into a training dataset with 80% of the sample and a test dataset with the rest for
5 times. The coefficient of determination R2 was calculated as 1 RSS
, where RSS was the residTSS
ual sum of squares and TSS was the total sum of squares.

Clustering, enrichment and association testing
To evaluate the genetic distance among samples in Asian and Caucasian, hierarchical clustering was applied based on the expression profiling of identified DEGs from RNA-seq. The IPA
software (http://www.ingenuity.com/products/ipa) was used to identify gene set enriched signaling pathways, upstream regulators and their target networks. Also, we applied linear regression, logistic regression and ordinal data analysis to investigate the association between the
risk score and clinical features. All data manipulations, statistical analyses and visualizations
were accomplished using R 3.0.2.
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Results
Cohort-common Differential Expression Genes (DEGs)
First, we investigated differential expression between tumor and paired normal tissues from
two ethnically different cohorts of patients with lung adenocarcinoma. The tumor-normal log
ratios of gene expression were consistent across Asian and Caucasian RNA-seq studies with
cohort specific variations (S1A Fig). 4418 genes had significant differential tumor-normal log
ratios of gene expression between populations; FDR adjusted p-values showed an overabundance of small values rather than being uniformly distributed (S1B Fig).
To identify consistent DEGs in both Caucasian and Asian cohorts, we designed a mixed
effect model with normally distributed residuals (Fig 1A). Cohort-common DEGs were highly
regulated in tumor tissues in both Asian and Caucasian studies (Fig 1B), which were also
found consistently to be highly differentially expressed in independent DNA microarray studies (Fig 1C). We compared the top 300 DEGs from population-specific (Asian-seq, Caucasianseq) and population-common analyses in Fig 1E (summary of the top 300 DEGs were shown
in S1–S3 Tables). All 118 DEGs identified in both Asian and Caucasian cohorts were detected
by the cohort-common analysis as well. Comparing the cohort-common genes from the RNAseq datasets and four population-specific gene sets from RNA-seq (Asian-seq, Caucasian-seq)
and microarray (Asian-array, Caucasian-array) datasets, we found a robust differential expression of the cohort-common genes (Fig 1F). As expected, the cohort-common analysis showed
greater power of detection because of the increased sample size, which identified more DEGs
than the cohort-specific analyses at the same significance thresholds (Fig 1D). Interestingly, we
also observed that Caucasian-seq analysis detected more DEGs than Asian-seq analysis (Fig
1D), which was probably due to the larger fold changes (Fig 1B).
Hierarchical clustering of all RNA-seq cohort-common and cohort-specific DEGs showed
that the expression profiling of the top tumor-normal DEGs in Caucasians and Asians were
highly consistent (Fig 2A). However, the expression for several genes, such as GDF10,
C10orf116, GCOM1, GART, WDR46, SLC25A10 and PECAM1 were population specific, in
which C10orf116 [24], GART [25] and SLC25A10 [26] had been reported to be functional in
metabolic processes. These results were consistent with the previous findings that Asians and
Caucasians had significantly different metabolic profiles [27]. Interestingly, several tumor samples in the Asian cohort showed a similar expression pattern with normal samples. These “normal-like” samples might account for the smaller tumor-normal log ratios in this cohort shown
in Fig 1B.
The 118 common DEGs were enriched in pathways related to cell proliferation, such as cell
cycle and biosynthesis of compounds including inosine-5’-phosphate, purine nucleotides, flavin etc (Fig 2B). Although TP53 showed increased expression (p-value = 1.55 × 10−11) and
MYC was slightly decreased (p-value = 0.002) in lung cancer tumors compared to paired normal tissues, TP53 target genes showed decreased expression (Fig 2C), consistent with the frequent observation of mutations of TP53 in adenocarcinomas [28]. Furthermore, MYC target
genes showed increased expression indicating potential MYC pathway activation.

A 10-marker panel for lung adenocarcinoma prognosis prediction
We tested the identified cohort-common DEGs for predicting tumor prognosis using the
TCGA dataset. Generally, tumor-normal DEGs had more power to predict prognosis than
non-DEGs (Fig 3A). 30 out of 118 cohort-common DEGs were significantly associated with
the risk of death with FDR adjusted p-values less than 0.05 (coefficients and significances were
shown in S2A Fig and c-indexes were shown in S2B Fig). From those 30 genes, 10 prognosis

PLOS ONE | https://doi.org/10.1371/journal.pone.0175850 April 20, 2017

5 / 14

Lung adenocarcinoma survival signatures across populations

Fig 1. Cohort-common and cohort-specific detections of DEGs. (A) Q-Q plot of residuals of one randomly selected gene from 4418 genes having
significant differential tumor-normal log ratios of gene expression between populations. (B) Comparison of detections from Asian and Caucasian RNA-seq
studies. (C) Comparison of detections from Asian and Caucasian microarray studies. (D) Comparison of discovery rates from population-common and
population-specific analyses. (E) Venn diagram of the top 300 DEGs from Asian and Caucasian RNA-seq studies. (F) Venn diagram of the top 300 DEGs
from all RNA-seq and microarray studies.
https://doi.org/10.1371/journal.pone.0175850.g001

markers were selected using LASSO with λ = 10−3 (S2C and S2D Fig), including five cell structural arrangement related genes (CAV1, FAM83A, PLEK2, KIF14 and ANLN), two cell cycle
and growth related genes (CCNB1 and RSPO1), an antioxidant gene CAT and two functionunknown genes FAM189A2 and NCKAP5. Risk scores were calculated as CAV1  0.12 +
FAM83A  0.017 + ANLN  0.01 + PLEK2  0.17 + KIF14  0.043 + CCNB1  0.015—RSPO1 
0.0048—FAM189A2  0.091—NCKAP5  0.022—CAT  0.036. With the mean of risk scores as
the threshold, we assigned patients into high risk and low risk groups. The high risk group had
significantly shorter survival time than the low risk group in both training (hazard ratio = 2.12,
p-value = 6.58 × 10−4, Fig 3B) and test datasets (hazard ratio = 3.63, p-value = 0.007, Fig 3C),
which were randomly split from the TCGA dataset. The risk scores showed statistical significance for patient prognosis for tumor stage I/II lung adenocarcinoma (hazard ratio = 2.51, pvalue = 4.19 × 10−5, S3 Fig Left). For tumor stage III/IV lung adenocarcinoma, high risk
patients had 2.46 times higher hazard risk than low risk patients, which was not statistical significance (p = 0.075) due to the limited number of late stage patients (S3 Fig Right). Consistent
with these results, patients with higher risk scores had a higher likelihood of death (Fig 3D
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Fig 2. Enrichment analyses of cohort-common DEGs. (A) Hierarchical clustering of gene expression of cohort-common and cohort-specific DEGs in
both Asian and Caucasian RNA-seq studies. (B) 118 cohort-common DEGs enriched pathways. (C) Upstream regulators and their target networks
enriched in 118 cohort-common DEGs.
https://doi.org/10.1371/journal.pone.0175850.g002

Top). As expected, the 10 selected markers showed significant alterations in gene expression
corresponding to the increased risk score and death proportion (Fig 3D). Consistently, each of
these 10 gene markers showed significant power in discriminating patients with low risk and
high risk of death (S4 Fig). CAV1 and NCKAP5 showed the weakest prognostic power individually but contribute to prognosis in the combined risk score.
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Fig 3. Prognosis markers. (A) Tumor-normal DEGs have more power to predict survival outcome. Genes were ranked according to the significance of
differential expression between tumor and normal tissues and were categorized into 20 bins evenly. The blue line indicates the rescaled discovery rate of
survival associated genes. (B, C) Kaplan-Meier plot of high-risk and low-risk groups from training and test datasets. (D) From top to bottom, (panel 1)
predicted risk scores; (panel 2) survival records of patients; (panel 3) gene expression of the 10 selected markers. Structural arrangement controlling
genes are indicated by red bars. X axis in all 3 panels shows the patients in the same order. (E) Statistics of multiple regression with risk score and other
clinical features as co-factors.
https://doi.org/10.1371/journal.pone.0175850.g003
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Fig 4. Association study of survival risk score with clinical features. (A) AJCC Tumor stage. (B) Smoking history, Non: Lifelong Non-smoker;
Ref<15: Current reformed smoker for < or = 15 years; Ref>15: Current reformed smoker for > 15 years; Ref-nd: Current Reformed Smoker, Duration Not
Specified; Cur: Current smoker.
https://doi.org/10.1371/journal.pone.0175850.g004

Prognostic power with clinical survival risk co-factors
We investigated the association of the 10-marker prognostic risk score with clinical features
including age, race, disease outcome, American Joint Committee on Cancer (AJCC) TNM
tumor staging information (cancer metastasis stage, neoplasm disease lymph node stage and
tumor stage), lung capacity indicators (FEV1, FEV1/FVC, DLCO) and smoking history. In Fig
4, we found that the risk score was significantly positively correlated with tumor stage. Also as
expected, current smokers had the highest risk scores, non-smokers had the lowest risk scores
and former smokers who have quit for longer durations had lower scores compared to more
recent quitters. A positive correlation with neoplasm disease lymph node stage, and a negative
correlation with weak lung capacity (low FEV1 and DLCO) were also observed (S5 Fig). However, we observed that associations between risk score and age, race, cancer metastasis stage or
FEV1/FCV percentage were not significant. The summary of statistics from association tests is
shown in S4 Table. To evaluate the predictive power of the risk score with those clinical co-factors including age, race, tumor stage and smoking history, we performed a multiple regression
analysis and found that risk score dominated the prediction with weak additional contributions from tumor stage and smoking history (Fig 3E).

Selected markers were applicable for both prognosis and discrimination
for both Asian and Caucasian populations
Above, we selected prognosis markers from the cohort-common DEGs with the expectation
that they have high predictive power in both populations. Here, we evaluate the performance
of the prediction model using this marker panel in an Asian microarray study (GSE8894). This
evaluation showed significant difference between the high-risk and low-risk groups (hazard
ratio = 3.25, p-value = 0.001) (Fig 5A). In contrast, 10 prognosis markers selected from the 104
Caucasian specific DEGs showed in Fig 1E presented less ability to discriminate high-risk
group from low-risk group (hazard ratio = 2.20, p-value = 0.028, figure not shown).
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Fig 5. Power of prognosis markers. (A) Kaplan-Meier plots of high-risk and low-risk patients grouped by prognosis markers on validate dataset
GSE8894. (B) Prognosis risk scores in all RNA-seq and microarray datasets. (C) ROC curves for tumor-normal discrimination by selected markers in all
RNA-seq and microarray datasets.
https://doi.org/10.1371/journal.pone.0175850.g005

Moreover, the selected prognosis markers had high power to differentiate tumor from normal tissue. A large difference of prognosis risk score was found between cancer and healthy
control tissues from all RNA-seq and microarray studies (Fig 5B). A logistic model was trained
for discriminating tumor from normal tissue, by which we obtained high power of discrimination showed in the ROC curve (Fig 5C).

Discussion
Our results demonstrate that although Asian and Caucasian studies produced consistent
genome-wide expression profiles, many genes have distinct tumor-normal alterations between
these two specific populations. Therefore, we designed a mixed effect model to include random
effects from ethnicity and patient subject for detecting the cohort-common DEGs. We selected
10 genes as biomarkers of prognosis from the cohort-common DEGs and found powerful discrimination of tumor and normal tissues in both Asian and Caucasian populations.
The differences between Asian and Caucasian cohort studies were captured and modeled
in our mixed effect model. Subject-average effects were estimated as well as subject-specific
effects from each subject, ethnicity and other confounding factors between studies. Thus, we
were able to characterize subject-specific confounders from individuals and populations, and
capture the true phenotype-genotype associations. Applying it, we detected 118 cohort-common DEGs and found that TP53 and MYC targeted genes were abnormally regulated in tumor
tissues. This indicates that for lung adenocarcinoma patients from both Asian and Caucasian
cohort studies, the apoptosis pathway might be turned down and cell-cycle pathway might be
powered up. Also, we observed that metabolic genes including C10orf116 [24], GART [25] and
SLC25A10 were differentially expressed between Caucasian and Asian populations. However,
additional studies are required to validate that these discrepancies are population-specific and
not due to technical variation.
This study demonstrated the relevance of tumor-normal discrimination and prognosis prediction in two populations using the same gene expression markers. Our findings provide the
logical basis for finding universal makers for both tumor discrimination and prognosis for
cost and time effectiveness. Also, our mixed effect model detected cohort-common DEGs to
provide a maker candidate pool for both Asian and Caucasian populations. With these logical
basis and candidate pool, we selected 10 markers and validated their capability for tumor
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discrimination and prognosis of lung adenocarcinoma in both Asian and Caucasian specific
studies with a high predictive power. Of the ten genes selected as biomarkers, five (CAV1,
FAM83A, PLEK2, KIF14 and ANLN) are associated with key events in cell division including
signal transduction, the actin cytoskeleton or in microtubule dynamics. All five genes were
positively associated with survival time, consistent with previous reports that these genes are
oncogenic in lung and other cancers [29–33]. The 10-gene biomarker panel also includes
CCNB1, which is a key cell-cycle regulator and known prognostic predictor of lung adenocarcinoma [34]. The antioxidant gene CAT was found to be negatively associated with the risk of
death. This is consistent with that the overexpression of CAT leads to a less aggressive phenotype of cancer cells [35, 36]. Despites several gene expression candidate marker sets have been
proposed [37–39], they are from single population studies and lack of reproducibility for clinical application. In the current study, we selected prognosis markers from the whole transcriptome RNA-seq quantification, aiming to achieve a higher prognosis power than previous
microarray studies or PCR studies of empirically selection markers. Furthermore, we considered the population genetics variations into our analysis thus our makers have higher potential
in application across populations compared to previous studies developed based on single
populations.
In clinical practice, tumor stage is the main prognostic indicator for treating lung adenocarcinoma. Surgical resection is the standard treatment for tumor stage I/II patients, whereas
chemotherapy and radiation are suggested to treat tumor stage III/IV patients. The 10-gene
marker panel demonstrated statistical significance for patient prognostication, particularly for
early stage lung adenocarcinoma, suggesting surgery may be insufficient for the high-risk early
patients and may be improved with additional adjuvant chemotherapy.
Prognostic risk scores from the 10-gene biomarker panel were significantly correlated with
known clinical survival risk factors including tumor stage, FEV1 and DLCO, and smoking history. However, this new panel showed the highest prognosis power in multivariate analysis.
Further in the future, other potential predictors will included in the model, such as mutations
of EGFR, HER2, BRAF or KRAS, fusions of RET, ALK or ROS1 and others.
In conclusion, this study uses a statistical framework to detect DEGs between tumor and
normal tissues that considers variances among patients and ethnicities, as well as confounding
factors such as microarray or RNA-seq platform and data processing strategies. Such a method
can help us understand the genes and signalling pathways with the largest effect sizes in ethnically diverse cohorts. We propose multifunctional markers for distinguishing tumor from normal tissue and prognosis for both populations studied. This study provides a strategy for
identifying biomarkers from high-throughput transcriptome profiling data across cohorts of
diverse patients.

Supporting information
S1 Fig. Comparison of tumor-normal gene expression alterations between Asian and Caucasian populations. (A) Comparison of tumor-normal log ratios from Asian and Caucasian
RNA-seq studies. (B) Distribution of p-values from differential testing on tumor-normal log
ratios.
(TIF)
S2 Fig. Selection of prognosis markers. (A) Univariate survival analysis statistics of genes
with FDR less than 0.05. (B) c-indexes of genes with FDR less than 0.05. (C) Cross-validated
deviance of LASSO fit. (D) Prediction statistics of selected markers.
(TIF)
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S3 Fig. Prognostic power of risk score in patients within early and late stages. Left: KaplanMeier plot of high risk and low risk groups of tumor stage I/II patients. Right: Kaplan-Meier
plot of high risk and low risk groups of tumor stage III/IV patients.
(TIF)
S4 Fig. Kaplan-Meier plots of each individual prognosis marker. Patients were grouped
based on the mean of gene expression value of each individual prognosis marker.
(TIF)
S5 Fig. Association study of survival risk score with clinical features. (A) AJCC Neoplasm
disease lymph node stage. (B) Pre-bronchodilator FEV1. (C) Post-bronchodilator FEV1. (D)
Diffusing capacity of the lungs for carbon monoxide (DLCO).
(TIF)
S1 Table. The top 300 DEGs from Asian-seq analyses.
(XLSX)
S2 Table. The top 300 DEGs from Caucasian-seq analyses.
(XLSX)
S3 Table. The top 300 DEGs from population-common analyses.
(XLSX)
S4 Table. The summary of statistics from association tests on 10-marker prognosis risk
score and clinical features.
(XLSX)
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